CXI Healthcare Technology Group씨엑스아이

CXI's shares have fallen sharply over the past year, while revenue and profit have shrunk from 2024 levels despite a still-high margin in 2025.

CXI Healthcare Technology Group is a Cayman Islands holding company that operates in China through subsidiaries selling health foods and skincare products. Its 2025 revenue was ₩297B, down 21.2% from 2024, with operating income of ₩50B and net income of ₩66B. The share price closed at ₩3,120 on 27 October 2026, down about 75% over one year.

What stands out

• 2025 revenue fell 21.2% to ₩297B, and net income fell from ₩159B in 2024 to ₩66B.
• Valuation multiples are very high, with a P/E of about 539 and a P/B of about 13.6, against a DCF base value of ₩142 per the data provided.
• The company reports ₩1.06T in cash against only ₩2B in borrowings, and a liabilities-to-equity ratio of 0.5%.
• Recent filings include several share acquisition decisions and a material report on a change in revenue or profit structure at a subsidiary.
• Recent news says CXI secured management control of a Chinese AI firm and is restructuring its business. The data does not give details of the deal's terms or effects.

What to watch

• Details and financial effects of the Chinese AI firm acquisition and restructuring, which the data does not yet describe.
• Follow-up filings on the amended material matters reports for equity acquisitions.
• Whether the 2026 annual report and AGC results change the revenue and profit trend; free cash flow is not available in the data.